Accuray (ARAY)
(Real Time Quote from BATS)
$1.73 USD
-0.04 (-2.26%)
Updated Sep 25, 2024 02:20 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Company Summary
Sunnyvale, CA-headquartered Accuray Inc. designs, develops, and sells radiosurgery and radiation therapy systems for treatment of tumors in the body. The company’s product suite includes the CyberKnife Systems and the TomoTherapy Systems.
The company primarily generates revenues by selling the CyberKnife and TomoTherapy Systems and providing ongoing services and upgrades to customers following installation of the CyberKnife System. Product revenues include sales of linear accelerators (linacs) for other uses. The company also offers optional hardware and software, technical enhancements, and upgrades to the CyberKnife and TomoTherapy System, as part ...
Company Summary
Sunnyvale, CA-headquartered Accuray Inc. designs, develops, and sells radiosurgery and radiation therapy systems for treatment of tumors in the body. The company’s product suite includes the CyberKnife Systems and the TomoTherapy Systems.
The company primarily generates revenues by selling the CyberKnife and TomoTherapy Systems and providing ongoing services and upgrades to customers following installation of the CyberKnife System. Product revenues include sales of linear accelerators (linacs) for other uses. The company also offers optional hardware and software, technical enhancements, and upgrades to the CyberKnife and TomoTherapy System, as part of its multi-year service plans.
The CyberKnife Systems are fully robotic stereotactic radiosurgery systems (SRS) and stereotactic body radiation therapy systems (SBRT) used to treat multiple types of cancer and tumors in the body. The CyberKnife Systems include: the CyberKnife G4, which includes the Fixed collimator; CyberKnife VSI System, which includes the Fixed and Iris collimators and the new CyberKnife M6 Series System, that comes in configurations with option of Fixed collimator, Iris collimator, and a MultiLeaf collimator, or MLC.
In the past, Accuray acquired TomoTherapy that develops advanced radiation therapies to treat multiple cancer types. TomoTherapy Systems include the Hi-Art System, delivering CT-guided, helical intensity modulated radiation therapy (IMRT); the TomoHD System, which includes both TomoHelical and TomoDirect treatment modalities, and the Tomo H Series Systems that come in configuration options of TomoH, TomoHD and TomoHDA and which includes one or more of the following options: TomoHelical, TomoDirect, High Performance VoLo Planning and TomoEdge Dynamic Jaws.
FY24 at a Glance
Accuray derives revenues from two sources — Product and Services.
Product revenues were $234.2 million (52.4% of total revenues in FY 2024; up 0.4% from FY 2023). Service revenues were $212.4 million (47.6%, down 0.9%).
General Information
Accuray Incorporated
1240 Deming Way
MADISON, WI 53717
Phone: 608-824-2800
Fax: 408-716-4601
Email: aman.patel@westwicke.com
Industry | Medical - Instruments |
Sector | Medical |
Fiscal Year End | June |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/5/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.04 |
Current Year EPS Consensus Estimate | -0.01 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 11/5/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 1.77 |
52 Week High | 3.10 |
52 Week Low | 1.40 |
Beta | 1.40 |
20 Day Moving Average | 677,868.94 |
Target Price Consensus | 6.17 |
4 Week | -24.36 |
12 Week | 1.14 |
YTD | -37.46 |
4 Week | -25.77 |
12 Week | -2.81 |
YTD | -47.96 |
Shares Outstanding (millions) | 100.27 |
Market Capitalization (millions) | 177.47 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | 200.00% |
vs. Previous Quarter | 150.00% |
vs. Previous Year | 13.52% |
vs. Previous Quarter | 32.79% |
Price/Book | 3.90 |
Price/Cash Flow | NA |
Price / Sales | 0.40 |
6/30/24 | -33.65 |
3/31/24 | -44.46 |
12/31/23 | -28.11 |
6/30/24 | -3.30 |
3/31/24 | -4.54 |
12/31/23 | -3.05 |
6/30/24 | 1.66 |
3/31/24 | 1.58 |
12/31/23 | 1.58 |
6/30/24 | 0.95 |
3/31/24 | 0.78 |
12/31/23 | 0.84 |
6/30/24 | -3.48 |
3/31/24 | -4.99 |
12/31/23 | -3.25 |
6/30/24 | -3.48 |
3/31/24 | -4.99 |
12/31/23 | -3.25 |
6/30/24 | -2.65 |
3/31/24 | -4.10 |
12/31/23 | -2.38 |
6/30/24 | 0.45 |
3/31/24 | 0.41 |
12/31/23 | 0.49 |
6/30/24 | 2.01 |
3/31/24 | 1.89 |
12/31/23 | 1.97 |
6/30/24 | 3.65 |
3/31/24 | 4.05 |
12/31/23 | 3.53 |
6/30/24 | 78.48 |
3/31/24 | 80.18 |
12/31/23 | 77.90 |